How do I subscribe to ongoing alerts?

Subscribe to /feed/company/cubist-pharmaceuticals-llc-a-subsidiary-of-merck-co-inc-rahway-new-jersey-usa.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-17 · How we verify

Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) pipeline: 3 marketed, 0 filed, 7 Phase 3, 2 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

3 marketed 0 filed 7 Phase 3 2 Phase 2 1 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
daptomycin (up to 14 days)	daptomycin (up to 14 days)	marketed	Cyclic lipopeptide antibiotic	Bacterial cell membrane	Infectious Disease
daptomycin and gentamicin	daptomycin and gentamicin	marketed
Semi-Synthetic Penicillin	Semi-Synthetic Penicillin	marketed	Beta-lactam antibiotic (semi-synthetic penicillin)	Penicillin-binding proteins (PBPs); bacterial cell wall peptidoglycan	Infectious Disease
CXA-201	CXA-201	phase 3	Fluoroquinolone antibiotic	Bacterial DNA gyrase and topoisomerase IV	Infectious Disease
CXA-201 and metronidazole	CXA-201 and metronidazole	phase 3	Rifamycin antibiotic (CXA-201) combined with nitroimidazole antibiotic (metronidazole)	Bacterial RNA polymerase (CXA-201); DNA/RNA synthesis in anaerobic organisms (metronidazole)	Infectious Disease
Nafcillin (or equivalent)	Nafcillin (or equivalent)	phase 3	Beta-lactam antibiotic (semi-synthetic penicillin)	Penicillin-binding proteins (PBPs)	Infectious Disease
Alviompan	Alviompan	phase 3			Other
Vancomycin (or equivalent)	Vancomycin (or equivalent)	phase 3	glycopeptide antibiotic	D-alanyl-D-alanine terminus of cell wall precursors	Infectious Diseases
Tedizolid Phophate	Tedizolid Phophate	phase 3	oxazolidinone antibiotic	50S ribosomal subunit	Infectious Diseases
CB-183,315	CB-183,315	phase 3	Bacterial protein synthesis inhibitor	Bacterial ribosome	Infectious Disease

Therapeutic area mix

Infectious Disease · 6
Infectious Diseases · 4
Other · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Bayer · 2 shared drug classes
Merck Sharp & Dohme LLC · 2 shared drug classes
Pfizer · 2 shared drug classes
Connect Biopharma Australia Pty Ltd · 1 shared drug class
Carolina Eyecare Physicians, LLC · 1 shared drug class
Daewon Pharmaceutical Co., Ltd. · 1 shared drug class
Fundacion Clinic per a la Recerca Biomédica · 1 shared drug class
Bayer AG · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA):

Cite this brief

Drug Landscape (2026). Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/cubist-pharmaceuticals-llc-a-subsidiary-of-merck-co-inc-rahway-new-jersey-usa. Accessed 2026-05-17.